EIND Cancer Information to Submit to Doctors

New Post Public Reply Private Reply Replies (3) Message Board
ohm20
759
EIND: Information to Submit to Doctors

I ran across some new information for the person I'm trying to convince to get an EIND for breast cancer. I also added the new posters from our April presentations. Her specific breast cancer is progesterone negative, estrogen positive, HER2 positive. The new information pertains to any estrogen positive or progesterone negative cancer.  Problems arise when our old friends the PI3K/AKT/mTOR and MAPK/ERK pathways are highly activated. In estrogen positive the estrogen can boost both pathways along with CCR5 itself doing so. Those pathways in return can increase estrogen reducing the effectiveness of any inhibitor being used. With progesterone its receptors decrease over time when a progesterone booster is being used leading to activation of the pathways. With both PI3K/AKT/mTOR and MAPK/ERK they drive tumor growth all on its own. Leronlimab of course downregulates both pathways restoring the effectiveness of those treatments.
I am appending the new information to the information in the old pinned post so it can be pinned in its place.

Here is a list of publications that I printed out for someone possibly seeking an EIND for breast cancer to give to their doctor. I also printed out the list of links and a cover letter for contacting Cytodyn. It's not TNBC so she's not eligible for the current or upcoming trial.

Contact Information

Website - www.cytodyn.com

Phone - 360-980-8524

Email - info@cytodyn.com

Cytodyn welcomes all requests for the use of it's drug leronlimab under the FDA's Emergency Investigational New Drug Program. The preferred method of contact by physicians or patients is through Cytodyn's email address. Cytodyn will respond with more information about the drug and the steps to take to initiate the EIND process.

Online Links to Publications

Leronlimab is associated with long-term survival in metastatic TNBC: Enhancing PD-L1 expression, ICI response, and modulates T cell exhaustion

Abstract - https://aacrjournals.org/cancerimmunolres/art...-with-long

Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...evised.pdf

Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

Abstract - https://aacrjournals.org/clincancerres/articl...llowing-PD

Poster - https://d1io3yog0oux5.cloudfront.net/_fb000f7..._FINAL.pdf

Long Term Survival with Leronlimab Treatment in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)

Poster - https://d1io3yog0oux5.cloudfront.net/_976f96f...28h%29.pdf

Leronlimab induces PD-L1 expression and is associated with long‑term survival with an ICI in PD-L1 low metastatic TNBC

Abstract (for April 19, 2026 presentation) - https://www.abstractsonline.com/pp8/#!/21436/...ation/9742

Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Publication - https://link.springer.com/article/10.1186/s13058-021-01391-1

Leronlimab induces PD-L1 expression and is associated with long-term survival with an ICI in PD-L1 low metastatic TNBC

https://d1io3yog0oux5.cloudfront.net/_8fabbae...P+3-21.pdf

Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with

refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study

https://d1io3yog0oux5.cloudfront.net/_bda4625...026_V6.pdf

The Role and Therapeutic Targeting of CCR5 in Breast Cancer

Publication - https://pdfs.semanticscholar.org/c499/b3b8f8d...32aa89.pdf

The CCL5/CCR5 Axis in Cancer Progression

Publication - https://www.mdpi.com/2072-6694/12/7/1765

Source: https://investorshangout.com/post/view?id=6822669


Progesterone +. Estrogen+, specific information

Leronlimab a humanized monoclonal antibody binds CCR5, blocking binding of it's C-C chemokine ligands (preferentially binding CCL-4 and CCL-5). Leronlimab downregulates both the PI3K/AKT/mTOR and MAPK/ERK pathways.

 CCL5/CCR5 axis in human diseases and related treatments

"CCL5/CCR5 axis focus on influencing the cell cycle of tumor cells through abnormally activating NF-κB, mTOR and PI3K/AKT signaling pathways. At the molecular level, the cell division-related genes like cyclin D1, c-Myc and Dad-1 are overexpressed at tumor cell surface. They cooperate with each other to strengthen the mitogenesis. Furthermore, mTOR-mediated glycolysis and ATP production provide sufficient energy for the growth of tumor cells. In this process, CCL5/CCR5 combination triggers mTOR signaling continuously for cell proliferation."

https://pmc.ncbi.nlm.nih.gov/articles/PMC8423937/



The Inflammatory Chemokine CCL5 and Cancer Progression

"More specifically, CCL5 contributes to the activation of the αvβ3 integrin and to cell migration through PI3K/Akt, which in turn activates IKKalpha/beta and NF-κB. NF-κB activation also can elevate the secretion of MMP-9 or promote invasion by increasing the secretion of both MMP-2 and -9 and by activating the ERK and Rac signaling [27]. CCL5 induces migration also by upregulating the activities of MMP-9 through STAT3 [28]. In other instances CCL5/CCR5 acts via MEK, ERK, and then NF-κB, resulting in the activations of αvβ3 integrin and contributing to cell migration.

Chemokines, by activating the tyrosine kinase receptors, the Jak-STAT, or the MAPK/ERK signaling pathway, also promote tumor cell proliferation. Exogenous CCL5 stimulates cell proliferation by inducing the mTOR pathway, leading to a rapid upregulation of cyclin D1, c-Myc, and Dad-1 expression. An additional mechanism based on the CCL5-CCR5 interaction can lead to increased cell proliferation: increased glucose uptake, increased ATP production, and enhanced glycolysis, associated with extracellular acidification"

https://onlinelibrary.wiley.com/doi/10.1155/2014/292376

====================================================================================================

Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies

"Endocrine therapy combined with mTOR inhibitors

The PI3K–AKT–mTOR pathway has also been implicated to play a crucial role in tumor proliferation and progression. Several studies showed that the upregulation of the PI3K–AKT–mTOR pathway interacts with the ER pathway and confers endocrine resistance... Another preclinical study showed that co-treatment with low concentrations of mTOR inhibitor RAD001 combining with either letrozole or fulvestrant could restore the response of the resistant cells with high Akt activity. In addition, it could also resensitize breast cancer cells that did not respond to letrozole or fulvestrant as a single agent"

https://pmc.ncbi.nlm.nih.gov/articles/PMC5558537/



The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

"The MAPK/ERK pathway is one of the most classical intracellular signaling pathways which is involved in tumor progression and drug resistance. The activation of the MAPK/ERK signaling axis phosphorylates ER, increases the sensitivity of ER to estrogen, and thereby contributes to endocrine therapy resistance. In addition, it communicates with other signaling pathways and cooperates to promote the proliferation and migration of tumor cells."

https://pmc.ncbi.nlm.nih.gov/articles/PMC10611521/#s7  

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 138

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 113

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 44

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Mimic Bets Virtual Patching Can Calm AI Patch Chaos

Updated Category News Views 16

Three ugly outages in four days can make even hardened technology buyers reconsider the sacred ritual of “patch immediately.” Mimic’s new Virtual Patching offering arrives squarely in that uncomfortable gap: a vulnerability is known, attackers may be moving fast, and the proper vendor update still needs testing before somebody detonates production. The company’s...

Continue Reading
Miami Office Puts Dubai Closer to U.S. Business Deal Flow

Updated Category News Views 68

Miami is not a random pin on a map; it is a deliberate front door to the Americas, and Dubai International Chamber has decided it needs someone standing in it. The chamber opened a representative office there on November 19, 2026, its second in the United States after launching in New York during the Dubai Business Forum – USA in November 2025. This is not the sort of...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 144

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 53

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 102

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Unveils New Wealth Management Tools for Advisors

Updated Category News Views 212

Orion Unveils New Wealth Management Tools for Advisors Orion, known for empowering financial advisors with cutting-edge wealth management solutions, is excited to announce a series of significant enhancements aimed at assisting advisors in servicing high-net-worth (HNW) and ultra-high-net-worth (UHNW) clientele. As new economic paradigms shift with generational wealth...

Continue Reading
Myriad Genetics Enhances Breast Cancer Research with Collaborations

Updated Category News Views 119

Myriad Genetics Expands Research Collaborations for Breast Cancer Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precision medicine, has recently embarked on a series of important research collaborations aimed at studying the application of molecular residual disease (MRD) testing in breast cancer. These initiatives leverage Myriad’s...

Continue Reading
Man Group PLC Discloses Significant Position in American Axle

Updated Category News Views 158

Significant Position Disclosure by Man Group PLC Man Group PLC, a global investment management firm, has made a notable disclosure concerning its significant interests in American Axle & Manufacturing Holdings, Inc. This disclosure falls under Rule 8.3 of the UK Takeover Code, which mandates disclosure by entities holding 1% or more of relevant securities in any company...

Continue Reading
Legal Protection Steps for Jasper Therapeutics Investors

Updated Category News Views 223

Understanding the Importance of Legal Counsel Deciding to invest in a company like Jasper Therapeutics, Inc. (NASDAQ: JSPR) can be a significant move, but it's crucial to be aware of the potential challenges that come with investing in securities. Individuals who have bought shares in Jasper Therapeutics between certain dates should pay close attention to upcoming...

Continue Reading
TotalEnergies Expands on Gas Strategy with Latest Acquisition

Updated Category News Views 124

TotalEnergies Expands on Gas Strategy with Latest Acquisition TotalEnergies SE (TTE) shares have shown an upward trend, particularly in premarket trading. Recently, the company announced a notable agreement with Lewis Energy Group that involves acquiring a significant 45% stake in its dry gas-producing assets located in the Eagle Ford Basin, Texas. Details of the...

Continue Reading